Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer

Cannot have received: IMNN-001 (IMNN-001)

prior treatment with IMNN-001

Cannot have received: immunotherapy

Prior treatment for high-grade non-mucinous epithelial ovarian, fallopian tube, or peritoneal cancer (e.g., immunotherapy, anticancer therapy, surgery, radiation therapy)

Cannot have received: anticancer therapy

Prior treatment for high-grade non-mucinous epithelial ovarian, fallopian tube, or peritoneal cancer (e.g., immunotherapy, anticancer therapy, surgery, radiation therapy)

Cannot have received: surgery

Prior treatment for high-grade non-mucinous epithelial ovarian, fallopian tube, or peritoneal cancer (e.g., immunotherapy, anticancer therapy, surgery, radiation therapy)

Cannot have received: radiation therapy

Prior treatment for high-grade non-mucinous epithelial ovarian, fallopian tube, or peritoneal cancer (e.g., immunotherapy, anticancer therapy, surgery, radiation therapy)

Cannot have received: chemotherapy

prior chemotherapy for any abdominal or pelvic tumor

Cannot have received: radiation therapy

Exception: Prior radiation for localized cancer of the breast, head and neck, or skin is permitted, if it was completed at least 3 years prior to registration, and the participant remains free of recurrent or metastatic disease.

prior radiotherapy to any portion of the abdominal cavity or pelvis is excluded

Cannot have received: chemotherapy

Exception: Prior adjuvant chemotherapy for localized breast cancer, if it was completed at least three years prior to registration, and that the participant remains free of recurrent or metastatic disease.

prior chemotherapy for any abdominal or pelvic tumor is excluded

Cannot have received: bevacizumab (bevacizumab)

will receive bevacizumab with the neoadjuvant or adjuvant treatment, or as maintenance will be excluded